Advances in the Diagnosis and Treatment of Heart Disease: A Comprehensive Approach in Internal Medicine
DOI:
https://doi.org/10.55204/scc.v2i2.e77Keywords:
Heart Disease, Coronary Heart Disease, Heart Failure, Diagnosis, TreatmentAbstract
Introduction: Cardiovascular diseases (CVD) group together numerous multifactorial pathologies. Incidence and mortality rates are decreasing worldwide, due to better strategies in both early diagnosis and treatment. It is important that the management of these diseases is carried out in a multidisciplinary manner.
Development: An article reviewing the documents of scientific societies on the treatment of cardiovascular disease and heart failure, as well as systematic reviews and current scientific studies was carried out through the search engines SCOPUS, WOS and Pubmed and Google Scholar both in Spanish. like in English.
Practical applications or future lines of research: In recent years, different lines of research have been developed such as cell treatment or the implementation of artificial intelligence with promising results.
Conclusions: Cardiovascular risk is attributed to modifiable risk factors, it is important that the main indicators of cardiovascular health are met: The evaluation of patients with cardiovascular disease requires stratification of cardiovascular risk and determining the severity of the disease. Pharmacological treatment should focus on the patient's needs
Downloads
References
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. doi:10.1161/CIR.0000000000000678
de la Peña A, Roca-Cusachs À, Suárez C, Bonet S. Riesgo vascular en las consultas de Medicina Interna. Estudio MICARE. Med Clínica. 2013;140(6):246-254. doi:10.1016/j.medcli.2012.05.043
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
Saba PS, Parodi G, Ganau A. From Risk Factors to Clinical Disease. J Am Coll Cardiol. 2021;77(11):1436-1438. doi:10.1016/j.jacc.2021.01.040
Cowie MR, Zakeri R. Preventing Heart Failure at the Population Level. JACC Heart Fail. 2019;7(3):214-216. doi:10.1016/j.jchf.2018.11.002
Rossello X, Dan GA, Dweck MR, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720-3826. doi:https://doi.org/10.1093/eurheartj/ehad191
Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. doi:10.1161/CIR.0000000000001168
Levy PD, Mukherjee D, Amsterdam E, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. J Am Coll Cardiol. 2021;78(22):e187-e285. doi:10.1016/j.jacc.2021.07.053
Siasos G, Tsigkou V, Bletsa E, et al. Antithrombotic Treatment in Coronary Artery Disease. Curr Pharm Des. 29:1-16. Accessed November 25, 2023. https://www.eurekaselect.com/article/134138
Deoker A, Lehker A, Mukherjee D. Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes. Curr Cardiol Rep. 2020;22(10):1-9. doi:10.1007/s11886-020-01370-6
Strauss MH, Hall AS, Narkiewicz K. The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases. Cardiovasc Drugs Ther. 2023;37(4):757-770. doi:10.1007/s10557-021-07248-1
Borghi C, Levy BI. Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis. Nutr Metab Cardiovasc Dis. 2022;32(4):815-826. doi:10.1016/j.numecd.2021.11.015
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
Falco L, Martucci ML, Valente F, Verrengia M, Pacileo G, Masarone D. Pathophysiology-Based Management of Acute Heart Failure. Clin Pract. 2023;13(1):206-218. doi:10.3390/clinpract13010019
Ghimire A, Fine N, Ezekowitz JA, Howlett J, Youngson E, McAlister FA. Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. Eur Heart J. 2019;40(26):2110-2117. doi:10.1093/eurheartj/ehz233
Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(10):1169-1186. doi:10.1002/ejhf.1531
Kowalska K, Walczak J, Femlak J, Młynarska E, Franczyk B, Rysz J. Empagliflozin—A New Chance for Patients with Chronic Heart Failure. Pharmaceuticals. 2021;15(1):47. doi:10.3390/ph15010047
Böhm M, Butler J, Mahfoud F, et al. Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial. Eur J Heart Fail. 2022;24(10):1883-1891. doi:10.1002/ejhf.2677
Baker C, Perkins SL, Schoenborn E, Biondi NL, Bowers RD. Pharmacotherapy Considerations in Heart Failure with Mildly-Reduced Ejection Fraction. J Pharm Pract. 2023;36(1):155-163. doi:10.1177/08971900211027315
Poglajen G, Frljak S, Zemljič G, et al. Stem Cell Therapy for Chronic and Advanced Heart Failure. Curr Heart Fail Rep. 2020;17(5):261-270. doi:10.1007/s11897-020-00477-9
Emerging Roles for Artificial Intelligence in Heart Failure Imaging. Heart Fail Clin. 2023;19(4):531-543. doi:10.1016/j.hfc.2023.03.005
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Karina Jessenia Jarrin Maisincho, William Esteban Quishpe Morillo, Jhon Alexander Ponce Alencastro, Xavier Enrique Mieles Borja, Gianella Marisol Loyola Diaz, Francisco Javier Guerra Brandt, Diana Mercedes Limones Espín
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the moral and patrimonial rights of their works. Since Prometeo Journal is an open access publication, readers can fully or partially reproduce its content as long as they properly credit the corresponding authors and the journal itself.
Our journal is governed by the international policies SHERPA/RoMEO: Green journal: They allow the self-archiving of both the pre-print (draft of a paper) and the post-print (the version corrected and reviewed by peers) and even the final version ( layout as it will be published in the journal).
See also "Copyright and licences".
